Surrozen (NASDAQ:SRZN) Earns “Sell (D-)” Rating from Weiss Ratings

Surrozen (NASDAQ:SRZN)‘s stock had its “sell (d-)” rating restated by stock analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Surrozen Stock Up 2.1%

NASDAQ:SRZN opened at $14.04 on Wednesday. The business’s 50 day moving average is $11.65 and its two-hundred day moving average is $10.04. Surrozen has a 52 week low of $5.90 and a 52 week high of $18.17. The company has a market cap of $120.32 million, a PE ratio of -0.97 and a beta of 0.63.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.09. The business had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 545.43% and a negative net margin of 274.42%. As a group, sell-side analysts expect that Surrozen will post -8.49 EPS for the current fiscal year.

Institutional Trading of Surrozen

Several hedge funds have recently made changes to their positions in the stock. Stempoint Capital LP raised its stake in Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares in the last quarter. RA Capital Management L.P. raised its stake in Surrozen by 140.3% during the 1st quarter. RA Capital Management L.P. now owns 679,130 shares of the company’s stock valued at $7,919,000 after acquiring an additional 396,550 shares in the last quarter. 5AM Venture Management LLC bought a new stake in Surrozen during the 1st quarter valued at $3,615,000. Stonepine Capital Management LLC raised its stake in Surrozen by 7.1% during the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after acquiring an additional 20,247 shares in the last quarter. Finally, Vivo Capital LLC bought a new stake in Surrozen during the 1st quarter valued at $3,032,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.